Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: An integrated analysis of clinical studies.

@article{Giovannoni2016SafetyAT,
  title={Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: An integrated analysis of clinical studies.},
  author={Gavin Giovannoni and Ludwig Kappos and Ralf Gold and Bhupendra O Khatri and Krzysztof W. Selmaj and Kimberly Umans and Steven J. Greenberg and Marianne T Sweetser and Jacob S. Elkins and Peter McCroskery},
  journal={Multiple sclerosis and related disorders},
  year={2016},
  volume={9},
  pages={36-46}
}
BACKGROUND Daclizumab has been evaluated in multicentre, randomised, double-blind studies for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS). Safety and tolerability are key considerations in MS treatment selection, as they influence adherence to medication. OBJECTIVE Evaluate the safety of daclizumab in patients with RRMS from an integrated analysis of six clinical studies. METHODS Patients treated with at least one dose of subcutaneous daclizumab 150mg or… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 10 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 17 references

A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: overview

  • RA Marrie, J Cohen, O Stuve, M Trojano, PS Sorensen, S Reingold
  • Mult Scler. 2015;21:263-81
  • 2015
1 Excerpt

Longterm Efficacy and Safety of Daclizumab HYP in Relapsing-Remitting Multiple Sclerosis: Results from the SELECTED Extension Study

  • R Gold, G Giovannoni, K Selmaj, E Havrdova, E-W Radue, T Sprenger
  • Consortium of Multiple Sclerosis Centers 2015…
  • 2015
1 Excerpt

Similar Papers

Loading similar papers…